This study investigated the effectiveness and the outcomes of rivaroxaban vs the standard of
care for venous thromboembolic prophylaxis in patients undergoing fracture-related surgery …

There is a substantial and ever-increasing need for anticoagulation treatment for the
prevention of thromboembolic events in patients at risk. The prevalence of atrial fibrillation …

Atrial fibrillation (AF) results in a substantial risk of mortality and morbidity from stroke and
thromboembolism, and thus, a cornerstone of AF management requires appropriate and …

Warfarin was the only oral anticoagulant available for the treatment of venous
thromboembolism for about half a century until the recent approval of novel oral agents …

Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment
of several thromboembolic disorders. Rivaroxaban does not require routine coagulation …

Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention
of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on …

A growing number of patients with atrial fibrillation are treated with oral anticoagulation
(OAC), and a large proportion of them will require surgical or other invasive procedures …

Abstract Objective Rivaroxaban is a United States Food and Drug Administration-approved
oral anticoagulant for venous thromboembolic disease; however, there is no information …

The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and
apixaban, are changing the way we manage thromboembolic disease. At the same time …

Background The compelling safety, efficacy and predictable effect of novel oral
anticoagulants (NOACs) is driving a rapid expansion in their therapeutic indications …